Pharmaust Limited (AU:NUZ) has released an update.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Neurizon Therapeutics Limited has filed an Investigational New Drug application with the FDA for its lead candidate, NUZ-001, to commence a Phase 2/3 clinical trial targeting ALS. This marks a significant milestone in the company’s efforts to address neurodegenerative diseases and could provide new hope for ALS patients. The trial is set to begin in the first half of 2025, pending FDA approval.
For further insights into AU:NUZ stock, check out TipRanks’ Stock Analysis page.
